9989 — Shenzhen Hepalink Pharmaceutical Co Share News
0.000.00%
Last trade - 00:00- HK$5.93bn
- HK$5.70bn
- CNY5.48bn
Brief: Shenzhen Hepalink Pharmaceutical Group Posts QTRLY Net Profit Attributable Of RMB156.6 Million
Brief: Shenzhen Hepalink Pharmaceutical Posts Profit Attributable RMB646.7 Million For Year
Brief: Shenzhen Hepalink Pharmaceutical Says Enoparin Approved In Argentina
Brief: Shenzhen Hepalink Pharmaceutical Says H1710 Injection Received Approval For From NMPA
Brief: Shenzhen Hepalink Pharmaceutical Got Certificate Of GMP Compliance Of A Manufacturer
Brief: Shenzhen Hepalink Pharmaceutical Sees FY Net Profit Attributable RMB589.00 Mln To RMB711.00 Mln
Brief: Shenzhen Hepalink Pharmaceutical Sees HY Net Profit Attributable RMB642.28 Mln To RMB734.82 Mln
Brief: Shenzhen Hepalink Pharmaceutical Posts Qtrly Net Profit Attributable RMB155.0 Mln
Brief: Shenzhen Hepalink Pharmaceutical Announces FY Loss Attributable Of RMB783.3 Mln
Brief: Shenzhen Hepalink Pharmaceutical Says Exarane Approved By New Zealand Medicines And Medical Devices Safety Authority
Brief: Shenzhen Hepalink Pharmaceutical Says Sees FY Net Loss Attributable RMB924.0 MLN- RMB647.0 MLN
Brief: Shenzhen Hepalink Pharmaceutical Proposes Offering And Listing Of Hightide Therapeutics
Brief: Shenzhen Hepalink Pharmaceutical Sees HY Net Profit Attributable RMB98.0 Mln-RMB127.0 Mln
Brief: Shenzhen Hepalink Pharma Elects Chairman
Brief: Shenzhen Hepalink Pharmaceutical Says Unit Entered Distribution & Supply Deal
Brief: Shenzhen Hepalink Pharmaceutical Group Proposes To Appoint Zhang Ping As Executive Director
Brief: Shenzhen Hepalink Pharmaceutical's 2022 Net Profit Down 202.0% Y/Y
Brief: Shenzhen Hepalink Pharmaceutical Says Oncovent Biomedical Agreed To Grant Exclusive Rights To Orient Europharma
Brief: Shenzhen Hepalink Pharmaceutical Unit Notified That U.S. FDA Approved New Drug Application